Cellenkos®, Inc., a clinical-stage biotechnology company, developing allogeneic, tissue-targeted regulatory T cell (Treg) ...

Dr. Timothy Olson, a pediatric hematologist at Children's Hospital of Philadelphia, discusses the most current thinking on treatment of children with aplastic anemia. This video was recorded at the ...

A Prescription Drug User Fee Act target date of December 10, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...

GRAND RAPIDS, Mich. — At just 18 years old, Lilly VandenBosch has already faced a lifetime of challenges. Diagnosed with aplastic anemia, a rare blood disorder, at the age of 7, her journey has been ...

The US FDA has authorized Cellenkos to begin a Phase II trial of CK0801 in adults with aplastic anemia who have limited treatment options. The therapy aims to restore immune balance and reduce ...

Please provide your email address to receive an email when new articles are posted on . Outcomes after haploidentical transplant for severe aplastic anemia have improved significantly with use of post ...

What Is Omisirge, and Why Does It Matter? Omisirge (omidubicel-onlv) is a type of cell therapy made from umbilical cord blood. It helps your body make new blood cells after a stem cell transplant.

For first-line treatment of severe aplastic anemia, adding eltrombopag (Promacta) to standard immunosuppressive therapy improved the rate, speed, and depth of hematologic response in the phase III ...

Experts provide an update regarding current understanding and management of aplastic anemia in a new review. 1 Eliska Furlong, MD, PhD, with the Perth Children’s Hospital, in Australia, and colleague ...

Aplastic anemia is a rare disorder characterized by inadequate production of blood cells by the bone marrow. The bone marrow is a spongy tissue inside the bones, where all the blood cells (red blood ...